Travere Therapeutics Inc’s recently made public that its CHIEF MEDICAL OFFICER Inrig Jula unloaded Company’s shares for reported $81606.0 on Jan 05 ’26. In the deal valued at $40.18 per share,2,031 shares were sold. As a result of this transaction, Inrig Jula now holds 86,756 shares worth roughly $3.0 million.
Then, Inrig Jula sold 445 shares, generating $16,799 in total proceeds. Upon selling the shares at $37.75, the CHIEF MEDICAL OFFICER now owns 86,311 shares.
Before that, JULA INRIG bought 445 shares. Travere Therapeutics Inc shares valued at $16,799 were divested by the Officer at a price of $37.75 per share.
Citigroup reiterated its Travere Therapeutics Inc [TVTX] rating to a Buy in a research note published on October 31, 2025; the price target was $48. Citigroup also remained covering TVTX and reiterated its “Buy” recommendation on June 11, 2025. Cantor Fitzgerald started covering the stock on January 10, 2025. It rated TVTX as “an Overweight”.
Price Performance Review of TVTX
On Monday, Travere Therapeutics Inc [NASDAQ:TVTX] saw its stock fall -2.87% to $34.58. Over the last five days, the stock has lost -12.50%. Travere Therapeutics Inc shares have risen nearly 81.24% since the year began. Nevertheless, the stocks have fallen -9.50% over the past one year.
How much short interest is there in Travere Therapeutics Inc?
A steep rise in short interest was recorded in Travere Therapeutics Inc stocks on 2025-12-15, growing by 1.84 million shares to a total of 12.2 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 10.36 million shares. There was a rise of 15.09%, which implies that there is a positive sentiment for the stock.
